{"brief_title": "Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)", "brief_summary": "This is a Phase II, open-label, multicenter, single-arm, exploratory \"proof of concept\" study. Diflomotecan (7 mg fixed dose) will be administered as a 20-minute IV infusion once every 3 weeks in patients with sensitive small cell lung cancer (SCLC) with progressive disease after first-line treatment with a platinum-based regimen.", "condition": "Small Cell Lung Cancer", "intervention_type": "Drug", "intervention_name": "Diflomotecan (BN80915)", "criteria": "Main Inclusion Criteria: - Documented small cell lung cancer (SCLC) - Measurable disease - One line of previous chemotherapy, including any platinum analogue, and excluding any camptothecin analogues, with objective response and relapsed no less than 3 months Main Exclusion Criteria: - Uncontrollable brain metastasis - Treated with an investigational drug within 30 days", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00080015.xml"}